Anavex Life Sciencesの空売り状況は、投資家がAnavex Life Sciencesの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Anavex Life Sciences (NASDAQ:AVXL) 株価情報, 空売り情報

Anavex Life Sciences

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences Corp

WIIM

AVXL

Anavex Life Sciences shares are trading higher after the company revealed the publication of its peer-reviewed oral blarcamesine Phase IIb/III data in the Journal of Prevention of Alzheimer's Disease.

D. Boral Capital analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) with a Buy and maintains $46 price target.

News

Price Target

Analyst Ratings

D. Boral Capital Maintains Buy on Anavex Life Sciences, Maintains $46 Price Target

Anavex Life Sciences Reveals Peer-reviewed Publication Of Oral Blarcamesine Phase IIb/III Data In Journal Of Prevention Of Alzheimer's Disease

Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that over three years of continuous treatment with blarcamesine (ANAVEX&#xAE;2-73) demonstrated significantly reduced clinical decline showing continued clinically and meaningful benefit for early Alzheimer's disease patients.

Anavex Reports Long-Term Benefits of Blarcamesine in Slowing Early Alzheimer's Disease Progression

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/27/24</td>
<td>$26.50</td>
<td>$152.0K</td>
<td>24.2K</td>
<td>8.7K</td>
</tr>
<tr>
<td>TLRY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.50</td>
<td>$34.6K</td>
<td>54.8K</td>
<td>5.9K</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$30.00</td>
<td>$195.0K</td>
<td>6.7K</td>
<td>1.8K</td>
</tr>
<tr>
<td>IOVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$7.50</td>
<td>$41.6K</td>
<td>7.8K</td>
<td>1.7K</td>
</tr>
<tr>
<td>AVXL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$17.00</td>
<td>$57.1K</td>
<td>1.5K</td>
<td>1.4K</td>
</tr>
<tr>
<td>LQDA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$10.00</td>
<td>$34.0K</td>
<td>1.8K</td>
<td>93</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$410.00</td>
<td>$28.2K</td>
<td>701</td>
<td>63</td>
</tr>
<tr>
<td>TMDX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$75.00</td>
<td>$33.4K</td>
<td>94</td>
<td>41</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$275.00</td>
<td>$30.0K</td>
<td>29</td>
<td>24</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$280.00</td>
<td>$26.1K</td>
<td>848</td>
<td>8</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we notice a call option trade that happens to be bearish, expiring in 1 day(s) on December 27, 2024. This event was a transfer of 8000 contract(s) at a $26.50 strike. The total cost received by the writing party (or parties) was $152.0K, with a price of $19.0 per contract. There were 24292 open contracts at this strike prior to today, and today 8717 contract(s) were bought and sold. 
• Regarding TLRY (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>), we observe a call option sweep with bullish sentiment. It expires in 22 day(s) on January 17, 2025. Parties traded 1500 contract(s) at a $1.50 strike. This particular call needed to be split into 30 different trades to become filled. The total cost received by the writing party (or parties) was $34.6K, with a price of $23.0 per contract. There were 54857 open contracts at this strike prior to today, and today 5953 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a call option trade that happens to be bearish, expiring in 22 day(s) on January 17, 2025. This event was a transfer of 1000 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $195.0K, with a price of $195.0 per contract. There were 6719 open contracts at this strike prior to today, and today 1888 contract(s) were bought and sold. 
• For IOVA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>), we notice a call option trade that happens to be bearish, expiring in 22 day(s) on January 17, 2025. This event was a transfer of 757 contract(s) at a $7.50 strike. The total cost received by the writing party (or parties) was $41.6K, with a price of $55.0 per contract. There were 7847 open contracts at this strike prior to today, and today 1775 contract(s) were bought and sold. 
• Regarding AVXL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>), we observe a call option sweep with bearish sentiment. It expires in 204 day(s) on July 18, 2025. Parties traded 200 contract(s) at a $17.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $57.1K, with a price of $285.0 per contract. There were 1543 open contracts at this strike prior to today, and today 1410 contract(s) were bought and sold. 
• Regarding LQDA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>), we observe a call option sweep with bearish sentiment. It expires in 386 day(s) on January 16, 2026. Parties traded 83 contract(s) at a $10.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $34.0K, with a price of $410.0 per contract. There were 1892 open contracts at this strike prior to today, and today 93 contract(s) were bought and sold. 
• Regarding VRTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), we observe a call option sweep with bullish sentiment. It expires in 22 day(s) on January 17, 2025. Parties traded 25 contract(s) at a $410.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $28.2K, with a price of $1130.0 per contract. There were 701 open contracts at this strike prior to today, and today 63 contract(s) were bought and sold. 
• For TMDX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>), we notice a put option sweep that happens to be bullish, expiring in 112 day(s) on April 17, 2025. This event was a transfer of 18 contract(s) at a $75.00 strike. This particular put needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $33.4K, with a price of $1860.0 per contract. There were 94 open contracts at this strike prior to today, and today 41 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a call option sweep with bullish sentiment. It expires in 141 day(s) on May 16, 2025. Parties traded 23 contract(s) at a $275.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $30.0K, with a price of $1305.0 per contract. There were 29 open contracts at this strike prior to today, and today 24 contract(s) were bought and sold. 
• For CI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), we notice a put option trade that happens to be bullish, expiring in 386 day(s) on January 16, 2026. This event was a transfer of 8 contract(s) at a $280.00 strike. The total cost received by the writing party (or parties) was $26.1K, with a price of $3266.0 per contract. There were 848 open contracts at this strike prior to today, and today 8 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

AMGN

Hims & Hers Health, Inc. Class A Common Stock

HIMS

IOVA

LQDA

TLRY

TMDX

VRTX

10 Health Care Stocks With Whale Alerts In Today's Session

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>HC Wainwright &amp; Co. raised Anavex Life Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) price target from $40 to $42. HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintained a Buy rating. Anavex Life Sciences shares closed at $10.87 on Tuesday. <a href="https://www.benzinga.com/quote/AVXL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James raised the price target for Kemper Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMPR#NYSE">KMPR</a>) from $75 to $82. Raymond James analyst C. Gregory Peters maintained a Strong Buy rating. Kemper shares closed at $65.25 on Tuesday. <a href="https://www.benzinga.com/quote/KMPR/analyst-ratings">See </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">how other analysts view this stock.</a></li>
<li>Needham boosted the price target for ACV Auctions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACVA#NASDAQ">ACVA</a>) from $26 to $28. Needham analyst Chris Pierce maintained a Buy rating. ACV Auctions shares closed at $21.67 on Tuesday. <a href="https://www.benzinga.com/quote/ACVA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. cut the price target for PolyPid Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPD#NASDAQ">PYPD</a>) from $14 to $11. HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintained a Buy rating. PolyPid shares closed at $2.97 on Tuesday. <a href="https://www.benzinga.com/quote/PYPD/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42669200/wall-streets-most-accurate-analysts-give-their-take-on-3-utilities-stocks-with-over-4-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Utilities Stocks With Over 4% Dividend Yields</a></li>
</ul>

Markets

Trading Ideas

ACVA

KMPR

PYPD

Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) with a Buy and raises the price target from $40 to $42.

HC Wainwright & Co. Maintains Buy on Anavex Life Sciences, Raises Price Target to $42

U.S. stocks were higher, with the Dow Jones index gaining over 100 points on Tuesday.
Shares of Greenfire Resources Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFR#NYSE">GFR</a>) rose sharply during Tuesday's session after Waterous Energy Fund acquired 9,311,424 common shares and 2,654,179 common share purchase <a href="https://www.benzinga.com/quote/GFR/news">warrants of the company.</a>
Greenfire Resources shares jumped 9.7% to $6.80 on Tuesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Alpha Teknova, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKNO#NASDAQ">TKNO</a>) shares jumped 23.7% to $9.50.</li>
<li>Rumble Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUM#NASDAQ">RUM</a>) gained 16.6% to $15.21. Rumble recently announced it has entered into a definitive agreement for a strategic investment of $775 million from Tether</li>
<li>China Yuchai International Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYD#NYSE">CYD</a>) gained 15.8% to $10.73.</li>
<li>SEALSQ Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>) jumped 13.8% to $5.58. The sector has recently seen increased interest.</li>
<li>Hut 8 Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) gained 10.6% to $23.95. Shares of crypto-related stocks traded higher amid a rise in the price of Bitcoin.</li>
<li>Anavex Life Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) rose 7.8% to $12.06. Anavex Life Sciences, on Monday, announced better-than-expected fourth-quarter financial results.</li>
<li>TeraWulf Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) gained 7.5% to $6.24. Shares of crypto-related stocks traded higher amid a rise in the price of Bitcoin.</li>
<li>MicroStrategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) rose 6.5% to $353.34. Shares of crypto-related stocks traded higher amid a rise in the price of Bitcoin.</li>
<li>Bitdeer Technologies Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) jumped 6% to $21.75. Shares of crypto-related stocks traded higher amid a rise in the price of Bitcoin.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42669200/wall-streets-most-accurate-analysts-give-their-take-on-3-utilities-stocks-with-over-4-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Utilities Stocks With Over 4% Dividend Yields</a></li>
</ul>

Intraday Update

Movers

BTDR

LAES

MSTR

TKNO

WULF

Greenfire Resources, Hut 8, TeraWulf, MicroStrategy And Other Big Stocks Moving Higher On Tuesday

Anavex Life Sciences shares are trading higher after the company announced better-than-expected Q4 financial results.

U.S. stocks were lower, with the Dow Jones index falling over 300 points on Monday.
Shares of Honda Motor Co., Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMC#NYSE">HMC</a>) rose sharply during Monday's session after the company announced it agreed to begin discussions and consideration toward a business <a href="https://www.benzinga.com/24/12/42642773/honda-nissan-start-merger-talks">integration with Nissan Motor.</a>
Nissan and Honda are planning to establish a joint holding company that will serve as the parent company for both Nissan and Honda. The joint holding parent company will be listed on the Tokyo Stock Exchange and Nissan and Honda will subsequently be delisted. The listing of the joint holding company is scheduled for August 2026.
Honda Motor shares jumped 13.5% to $27.13 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Rumble Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUM#NASDAQ">RUM</a>) shares jumped 75% to $12.59 after the company announced it has entered into a definitive agreement for a strategic investment of $775 million from Tether.</li>
<li>Despegar.com, Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DESP#NYSE">DESP</a>) gained 32.2% to $19.36. The company announced it will be acquired by Prosus in $1.7 Billion deal.</li>
<li>Anavex Life Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) surged 32.2% to $11.47 following fourth-quarter results. The company's Alzheimer&#8217;s Drug Blarcamesine was accepted for a review by European regulators.</li>
<li>Playa Hotels &amp; Resorts N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLYA#NASDAQ">PLYA</a>) gained 28.8% to $12.38 after Hyatt Hotels disclosed it executed an exclusivity agreement to potentially acquire the company.</li>
<li>Rigetti Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) shares rose 21.8% to $11.42. The company announced it has launched its 84-Qubit Ankaa 3 System and achieved 99.5% Median Two-Qubit Gate Fidelity Milestone.</li>
<li>Red Cat Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) surged 14.6% to $12.32.</li>
<li>D-Wave Quantum Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NASDAQ">QBTS</a>) gained 13.2% to $7.29.</li>
<li>New Fortress Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFE#NASDAQ">NFE</a>) rose 10.7% to $13.24 after Stifel maintained a Buy rating and raised its price target from $16 to $17.</li>
<li>FormFactor, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORM#NASDAQ">FORM</a>) gained 6% to $45.32.</li>
<li>Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) rose 3.9% to $228.60.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></li>
</ul>

AVGO

DESP

FORM

PLYA

QBTS

RCAT

RGTI

Honda Motor, Rumble, Despegar.com And Other Big Stocks Moving Higher On Monday

Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 12.5 percent. This is a 16.67 percent decrease over losses of $(0.12) per share from the same period last year.

Earnings

Earnings Beats

Anavex Life Sciences Q4 2024 GAAP EPS $(0.14) Beats $(0.16) Estimate; Cash Of $132.2M

Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for blarcamesine (ANAVEX&#xAE;2-73), an investigational drug for the treatment of Alzheimer's disease. The Company is looking forward to working with the EMA.
Blarcamesine is an orally once daily administered small molecule for the potential treatment of patients with Alzheimer's disease.

Government

Regulations

Anavex's Alzheimer's Drug Blarcamesine Accepted for Review by European Regulators

U.S. stock futures advanced on Monday following a tumultuous week which included the Federal Reserve&#8217;s hawkish rate cut on Wednesday and a &#8220;<a href="https://www.benzinga.com/general/travel/24/12/42627563/wall-street-rallies-as-soft-inflation-data-fuels-dip-buying-bonds-rebound-travel-stocks-soar-whats-driving-markets-friday">Triple Witching</a>&#8221; hour session on Friday. Two out of the four major index futures were trading higher in premarket trade.
The 10-year and two-year Treasury yields stood at 4.53% and 4.32%, respectively. The probability of having no change in the interest rates for the upcoming Jan. 31, 2025 decision was at 91.4%, according <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">to</a> CME Group&#8217;s FedWatch Tool.
Trading schedules will be adjusted for the Christmas holiday week. All markets will be closed on Wednesday. Trading hours will be shortened on Christmas Eve.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.23%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.07%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.06%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.15%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Monday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was up 0.09% to $591.73 and the Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rose 0.23% to $519.04, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From The Last Session
Risk appetite returned to Wall Street on <a href="https://www.benzinga.com/general/travel/24/12/42627563/wall-street-rallies-as-soft-inflation-data-fuels-dip-buying-bonds-rebound-travel-stocks-soar-whats-driving-markets-friday">Friday</a>, giving investors some relief. November&#8217;s inflation data came in softer than expected, offering a glimmer of hope that the Federal Reserve may ease its aggressive monetary tightening.
The Personal Consumption Expenditure (PCE) price index, the Fed&#8217;s preferred inflation gauge, rose 2.4% year-over-year, below the anticipated 2.5%. Core PCE, which excludes volatile food and energy prices, also undershot expectations, climbing 2.8% instead of the projected 2.9%.
This unexpected cooling of inflation sparked a jubilant rally across all major indices. The S&amp;P 500 surged 1.09%, with every sector contributing to the gains. Investors cheered the reprieve from persistent inflationary pressures.
The real estate sector led the charge, experiencing a sharp rebound after being particularly hard-hit by the Fed&#8217;s recent hawkish stance. Small-cap stocks, represented by the Russell 2000, also posted strong gains of 0.94%, buoyed by a significant recovery in regional banks. 
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>1.03%</td>
<td>19,572.60</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>1.09%</td>
<td>5,930.85</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>1.18%</td>
<td>42,840.26</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.94%</td>
<td>2,242.37</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
The number of advancers surpassed the decliners among the S&amp;P 500 index constituents on Friday after a 14-day streak of negative market breadth. Ryan Detrick, the global market strategist at Carson Research highlighted how the markets have performed after previous long streaks ended.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Record 14 days in a row of more declining stocks than advancing stocks for the S&amp;P 500 ended on Friday. Here&#39;s what happened after previous long streaks ended. &#x1f4aa; <a href="https://t.co/WV6PU7juQF">pic.twitter.com/WV6PU7juQF</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1871010953510142270?ref_src=twsrc%5Etfw">December 23, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
According to the data shared by him, over the past four decades, there have been only five other instances where the S&amp;P 500 experienced a period of ten or more consecutive days of negative breadth. Additionally, the index was higher by an average of 17.9% a year later after all five times.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Going back 40 years, there have been five other times the S&amp;P 500 had more decliners than advancers for 10 consecutive days or more. A year later? Higher all five times and up 17.9% on avg. <a href="https://t.co/eYCUpiz4PU">pic.twitter.com/eYCUpiz4PU</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1871016225993601258?ref_src=twsrc%5Etfw">December 23, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Along with this, the market breadth turned positive with 89% of the stocks rising on Friday as compared to only 4% on Wednesday. This divergence also led the index to be higher a year later by at least 92.3% of the time since 1985.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Less than 4% advancers on the S&amp;P 500 on Wednesday, but 89% on Friday. Previous times saw a flush and then major buying two days later? Negative 1 and 3 mos later on avg, but higher a year later 12 out of 13 times (92.3%). <a href="https://t.co/yqfV0tBFUV">pic.twitter.com/yqfV0tBFUV</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1871023980074963222?ref_src=twsrc%5Etfw">December 23, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
According to Gary Alexander at Navellier &amp; Associates, &#8220;The S&amp;P 500 delivers an average of zero gains in the first half of December (and 0.3% through December 15 this year) but averages 1.35% in the second half, the best half-month of the 24 half-months each year.&#8221;
&#8220;Core PCE (Personal Consumption Expenditure, excluding food and energy), the key inflation metric for the Fed, came in at 0.1% for November, below forecast and the lowest since June. This caught the market off guard, in a good way, as the rhetoric from Jerome Powell regarding sticky inflation had led the market to expect a surprise in the other direction,&#8221; said Louis Navellier of Navellier &amp; Associates.
&#8220;The traditional Santa Rally is the last 5 trading days of the year and the first 2 of the New Year. It may still be in the cards,&#8221; he added.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How To Trade Futures</a>
Upcoming Economic Data
A few important data points are slated to be released in this truncated week that will help investors determine the future course of action.
<ul>
<li>On Monday, consumer confidence for December will be released at 10:00 a.m., ET.</li>
</ul>
<ul>
<li>On Tuesday, November&#8217;s data for durable goods orders and durable goods minus transportation will be released at 8:30 a.m., ET.</li>
</ul>
<ul>
<li>New home sales for November will be released at 10:00 a.m. ET.</li>
</ul>
<ul>
<li>On Wednesday, there will be a day&#8217;s break for Christmas.</li>
</ul>
<ul>
<li>On Thursday, initial jobless claims data till Dec. 21 will announced at 8:30 a.m. ET.</li>
</ul>
<ul>
<li>On Friday, November&#8217;s data for the advanced U.S. trade balance in goods, advanced retail inventories, and advanced wholesale inventories will be announced at 8:30 a.m., ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Qualcomm Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) was up 3.02% in premarket after it bagged a key win in its legal battle against semiconductor design company Arm Holdings Plc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>), which was down 3.52%.</li>
</ul>
<ul>
<li>Anavex Life Sciences Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) was up 0.23% as analysts expect it to post a quarterly loss at 16 cents per share before the opening bell.</li>
</ul>
<ul>
<li>Brenmiller Energy Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNRG#NASDAQ">BNRG</a>) was up 32.75% after the company on Friday said that it was awarded ISO/IEC 27001:2022 certification.</li>
</ul>
<ul>
<li>Sealsq Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>) was up 31.27% after it announced the offering of 13,157,896 common stock at $1.90 per share.</li>
</ul>
<ul>
<li>MicroStrategy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) fell 1.69%, and Palantir Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) was up 1.42% in premarket trade.</li>
</ul>
<ul>
<li>Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) rose by 0.74% and Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) was up by 1.20% in premarket.</li>
</ul>
Commodities, Gold And Global Equity Markets:
Crude oil futures were lower in the early New York session by 0.32% to hover around $69.24 per barrel.
The gold spot index was down by 0.41% to $2,634.16 per ounce. The Dollar Index was up 0.42% to 108.073 level.
Asian markets advanced on Friday, as Hong Kong&#8217;s Hang Seng, South Korea&#8217;s Kospi, Japan&#8217;s Nikkei 225, India&#8217;s S&amp;P BSE Sensex, China&#8217;s CSI 300 and Australia&#8217;s ASX 200 index rose. European markets were mixed.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/12/42640010/palantir-and-anduril-reportedly-lead-consortium-partner-with-spacex-and-openai-to-compete-against-traditional-defense-contractors-in-850-billion-us-military-market">Palantir And Anduril Reportedly Lead Consortium, Partner With SpaceX And OpenAI To Compete Against Traditional Defense Contractors In $850 Billion US Military Market</a></li>
</ul>
Photo courtesy: Wikimedia

Equities

Futures

Economics

Federal Reserve

Pre-Market Outlook

BNRG

MRNA

PLTR

QCOM

SMCI

US Stocks To Open Higher As Wall Street Expects 'Santa Rally' In Shortened Trading Week: MicroStrategy, Palantir, Qualcomm Among Stocks In Focus

The CNN Money Fear and Greed index showed some easing in the fear level, with the index moving to the &#8220;Fear&#8221; zone on Friday.
U.S. stocks settled higher on Friday, with the Dow Jones index surging almost 500 points during the session.
Even as the major indices recorded gains on Friday, all three averages fell last week. The Dow dipped around 2.3% to record its third losing week in a row. The S&amp;P 500 declined about 2%, while the Nasdaq Composite fell around 1.8% last week.
On the economic data front, the U.S. personal consumption expenditures price index rose 0.1% month-over-month in November down from 0.2% in each of the prior two months and compared to market estimates of 0.2%. The University of Michigan consumer sentiment rose to 74 in December, recording the highest level since April, versus a reading of 71.8 in November.
Carnival Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) reported better-than-expected earnings for its fourth quarter on Friday.
All sectors on the S&amp;P 500 closed on a positive note, with utilities, real estate, and information technology stocks recording the biggest gains on Friday.
The Dow Jones closed higher by around 498 points to 42,840.26 on Friday. The S&amp;P 500 rose 1.09% to 5,930.85, while the Nasdaq Composite surged 1.03% to close at 19,572.60 during Friday's session.
Investors are awaiting earnings results from Limoneira Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMNR#NASDAQ">LMNR</a>), Bridgeline Digital, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLIN#NASDAQ">BLIN</a>), and Anavex Life Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 28.1, the index moved to the &#8220;Fear&#8221; zone on Friday, versus a prior reading of 21.9.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></li>
</ul>
Photo courtesy: Shutterstock

BLIN

LMNR

Dow Jumps Around 500 Points But Records 3rd Straight Weekly Loss: Greed Index Moves To 'Fear' Zone

With U.S. stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Limoneira Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMNR#NASDAQ">LMNR</a>) to report a quarterly loss at 7 cents per share on revenue of <a href="https://www.benzinga.com/quote/LMNR/earnings">$42.45 million after</a> the closing bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Limoneira shares gained 2% to $26.83 in after-hours trading.</li>
<li>Qualcomm Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) bagged a key win in its legal battle against semiconductor design company Arm Holdings Plc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>). A federal jury in Delaware ruled that Qualcomm did not violate its licensing agreement with Arm, clearing a hurdle for the San Diego, California-<a href="https://www.benzinga.com/24/12/42633922/qualcomm-bags-win-in-chips-licensing-trial-against-arm-but-the-battle-is-not-over-yet">headquartered chipmaker</a>. Qualcomm shares gained 1.9% to $155.72 in the after-hours trading session.</li>
<li>Analysts expect Anavex Life Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) to post a quarterly loss at 16 cents per share before the opening bell. Anavex Life Sciences shares gained 0.2% to $8.65 in the after-hours trading session.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Brenmiller Energy Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNRG#NASDAQ">BNRG</a>) shares rose sharply in after-hours trading on Friday after the company said it was awarded ISO/IEC 27001:2022 certification. Brenmiller Energy shares surged 12% to $0.8440 in the after-hours trading session.</li>
<li>Analysts expect Bridgeline Digital Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLIN#NASDAQ">BLIN</a>) to post a quarterly loss at 5 cents per share on revenue of $3.87 million after the closing bell. Bridgeline Digital shares fell 0.7% to $1.48 in after-hours trading.</li>
</ul>
Check This Out:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></li>
</ul>
Photo courtesy: Shutterstock

Qualcomm, Limoneira And 3 Stocks To Watch Heading Into Monday

<h3>Companies Reporting Before The Bell</h3>
• Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) is expected to report earnings for its fourth quarter. 
<h3>Companies Reporting After The Bell</h3>
• Bridgeline Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLIN#NASDAQ">BLIN</a>) is estimated to report quarterly loss at $0.01 per share on revenue of $3.87 million. 
• Limoneira (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMNR#NASDAQ">LMNR</a>) is expected to report quarterly loss at $0.07 per share on revenue of $42.45 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Scheduled For December 23, 2024

Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced its upcoming presentation of topline long-term data from the Phase IIb/III ATTENTION-AD Open-Label-Extension (OLE) trial at the J.P. Morgan 2025 Healthcare Conference, taking place January 13–16, 2025, in San Francisco, CA.
The presentation will highlight new findings from the ATTENTION-AD study evaluating potential benefit of oral once daily blarcamesine (ANAVEX&#xAE;2-73) in early Alzheimer's disease. The data reflect up to 144 weeks of continuous treatment in the OLE phase, following the prior 48-week double-blind Phase IIb/III study, for a total of up to 192 weeks (~4 years) of safety and efficacy data.

Anavex Shares Alzheimer's Treatment Data at 2025 JP Morgan Healthcare Conference

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) with a Buy and maintains $40 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Anavex Life Sciences, Maintains $40 Price Target

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Anavex Life Sciences (AVXL – Research Report), boosting the price target to $42...

Anavex Life Sciences: Buy Rating Driven by European Approval Prospects and Strong Financial Position

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Anavex Life Sciences: Jumping In On-Time Ahead Early Alzheimer's Decision

Anavex Life Sciences: Jumping In On Time Ahead Of An Early Alzheimer's Decision

Anavex Life Sciences ($AVXL) finished 2024 with its stock surging roughly 130% in the last three months. It was catalyzed by news of significant pr...

Anavex Life Sciences (AVXL) Alzheimer Treatment Sends the Stock to New Heights

The Misconceptions About Anavex Life Sciences' Blarcamesine Phase 2b/3 Trial In Alzheimer's Disease

Playing The Odds Of Anavex Alzheimer's Drug Approval

Anavex (AVXL) Life Sciences announced that over three years of continuous treatment with blarcamesine demonstrated significantly reduced clinical d...

Anavex announces 3 years of treatment with blarcamesine show reduced decline

Anavex Seeks EU Approval, But The Data Says Otherwise

Latest data shows the largest indicative borrow rate increases among liquid option names include: Canoo (GOEV) 176.65% +7.65, Snow Lake Resources L...

Largest borrow rate increases among liquid names

ACRS

BIIB

BYND

FGEN

GOEV

JSPR

LITM

ONCY

PBYI

PHIO

RAPT

SLGL

STEM

TPIC

Health Care

Press Releases

Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer's Disease Journal

General

Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer's Disease to EMA

Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024

Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer's Disease Data at J.P. Morgan 2025 Healthcare Conference

Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024

Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer's Disease

Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update

Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer's Disease Patients

Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer's Disease

Comments

Anavex Life Sciences

空売り

Anavex Life Sciences (NASDAQ:AVXL) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル